Provided is a composition suitable for parenteral administration to a subject and which composition comprises daunorubicin and cytarabine encapsulated in liposomes in a mole ratio of daunorubicin: cytarabine of about 1:5, wherein said liposomes have a mean diameter in the range of 4.5 nm to less than 250 nm and wherein the pharmacokinetics of the composition are controlled by the liposomes, whereby the daunorubicin and cytarabine agents are to be delivered to a disease site in a coordinated fashion and thereby assuring that said ratio is maintained at the disease site.
